A Comparative Histological and Immunohistochemical Study on the Possible Therapeutic Effects of Empagliflozin and platelet-rich plasma Against Cisplatin Induced …
AA El-Shafei, RM Hassan… - Egyptian Journal of …, 2023 - ejh.journals.ekb.eg
Introduction and Objectives: Cisplatin is a highly effective chemotherapeutic drug used to
treat various cancers. However, cardiotoxicity is one of the most important adverse effects of …
treat various cancers. However, cardiotoxicity is one of the most important adverse effects of …
Molecular mechanism of empagliflozin cardioprotection in 5-fluorouracil (5-FU)-induced cardiotoxicity via modulation of SGLT2 and TNFα/TLR/NF-κB signaling …
MMM Refaie, S Shehata, M El-Hussieny… - Toxicological …, 2024 - Springer
One of the commoly used chemotherapeutic agents is 5-Fluorouracil (5-FU). Unfortunately,
the clinical administration of 5-FU is complicated with serious cardiotoxic effects and the safe …
the clinical administration of 5-FU is complicated with serious cardiotoxic effects and the safe …
[PDF][PDF] Potential Role of Empagliflozin to Ameliorate Doxorubicin Induced Cardiotoxicity in Male Rats
RN Albakaa, FA Rizij, RMA Hassan - J. Med. Chem. Sci, 2023 - researchgate.net
Empagliflozin (EMPA), a selective inhibitor of the sodium-glucose co-transporter 2, is
especially effective at regulating blood-sugar levels [1]. Compared to conventional optimum …
especially effective at regulating blood-sugar levels [1]. Compared to conventional optimum …
[PDF][PDF] EFFECT OF EMPAGLIFLOZIN ON CISPLATIN-INDUCED NEPHROTOXICITY IN ADULT MALE ALBINO RAT
WMS Ahmed, A Soliman, WM Abd-Elhay, M Nasr… - researchgate.net
Background: empagliflozin is currently available for the management of type 2 diabetes
mellitus and had a renoprotective effect. Cisplatin (CP) is used in the treatment of different …
mellitus and had a renoprotective effect. Cisplatin (CP) is used in the treatment of different …
Empagliflozin attenuates doxorubicin-induced cardiotoxicity
VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh… - Toxicology …, 2023 - academic.oup.com
In previous issues of the journal, we have just read with great interest the paper by chen
entitled “Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating …
entitled “Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating …
Metformin and dapagliflozin attenuate doxorubicin-induced acute cardiotoxicity in wistar rats: an Electrocardiographic, Biochemical, and Histopathological Approach
Doxorubicin is a widely used anticancer drug whose efficacy is limited due to its
cardiotoxicity. There is no ideal cardioprotection available against doxorubicin-induced …
cardiotoxicity. There is no ideal cardioprotection available against doxorubicin-induced …
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
V Quagliariello, M De Laurentiis, D Rea… - Cardiovascular …, 2021 - Springer
Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
[HTML][HTML] Cardioprotective and anti-inflammatory effects of empagliflozin during treatment with doxorubicin: A cellular and preclinical study
V Quagliariello, C Coppola, D Rea, C Maurea… - Annals of …, 2019 - Elsevier
Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduces the risk of hospitalization for heart failure or cardiovascular death, as seen in the …
2, reduces the risk of hospitalization for heart failure or cardiovascular death, as seen in the …
Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways
VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh… - Cardiovascular …, 2021 - Springer
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …
Empagliflozin protective effects against cisplatin-induced acute nephrotoxicity by interfering with oxidative stress and inflammation in Wistar rats
N Farrokh-Eslamlou, S Momtaz, A Niknejad… - Naunyn-Schmiedeberg's …, 2024 - Springer
Cisplatin (Cis) is a platinum-based antineoplastic drug used in various types of cancers. This
drug can induce nephrotoxicity as a cause of acute kidney injury (AKI) by inducing oxidative …
drug can induce nephrotoxicity as a cause of acute kidney injury (AKI) by inducing oxidative …